688176 Stock Overview
Engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jiangsu Yahong Meditech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.61 |
| 52 Week High | CN¥12.18 |
| 52 Week Low | CN¥4.61 |
| Beta | 0.70 |
| 11 Month Change | 8.87% |
| 3 Month Change | 43.58% |
| 1 Year Change | -31.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688176 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.7% | -1.8% | -2.6% |
| 1Y | -31.9% | -7.0% | 4.2% |
Return vs Industry: 688176 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 688176 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
| 688176 volatility | |
|---|---|
| 688176 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688176 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688176's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 411 | Kevin Pan | www.asieris.cn |
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer.
Jiangsu Yahong Meditech Co., Ltd. Fundamentals Summary
| 688176 fundamental statistics | |
|---|---|
| Market cap | CN¥4.27b |
| Earnings (TTM) | -CN¥403.23m |
| Revenue (TTM) | CN¥149.71m |
28.5x
P/S Ratio-10.6x
P/E RatioIs 688176 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688176 income statement (TTM) | |
|---|---|
| Revenue | CN¥149.71m |
| Cost of Revenue | CN¥30.99m |
| Gross Profit | CN¥118.72m |
| Other Expenses | CN¥521.95m |
| Earnings | -CN¥403.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 79.30% |
| Net Profit Margin | -269.34% |
| Debt/Equity Ratio | 3.2% |
How did 688176 perform over the long term?
See historical performance and comparison